Long Run Wealth Advisors’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
$1.72M Buy
69,160
+764
+1% +$19.3K 0.32% 53
2025
Q3
$1.74M Buy
68,396
+3,751
+6% +$92.6K 0.34% 50
2025
Q2
$1.57M Buy
64,645
+6,409
+11% +$149K 0.33% 52
2025
Q1
$1.48M Buy
58,236
+6,235
+12% +$163K 0.33% 52
2024
Q4
$1.38M Buy
52,001
+5,916
+13% +$160K 0.33% 52
2024
Q3
$1.33M Buy
46,085
+6,121
+15% +$179K 0.31% 57
2024
Q2
$1.12M Buy
39,964
+3,072
+8% +$84.6K 0.28% 62
2024
Q1
$1.02M Buy
36,892
+3,025
+9% +$83.9K 0.27% 63
2023
Q4
$975K Buy
33,867
+1,557
+5% +$47.1K 0.28% 62
2023
Q3
$1.07M Buy
32,310
+1,328
+4% +$47K 0.35% 54
2023
Q2
$1.14M Buy
30,982
+1,023
+3% +$39.8K 0.36% 57
2023
Q1
$1.22M Buy
29,959
+1,541
+5% +$66.6K 0.42% 55
2022
Q4
$1.46M Sell
28,418
-660
-2% -$31.6K 0.52% 47
2022
Q3
$1.27M Buy
29,078
+4,851
+20% +$236K 0.5% 46
2022
Q2
$1.27M Sell
24,227
-143
-0.6% -$7.29K 0.49% 45
2022
Q1
$1.26M Sell
24,370
-1,091
-4% -$56.6K 0.44% 49
2021
Q4
$1.5M Buy
+25,461
New +$1.26M 0.52% 45

Other funds holding PFE

Long Run Wealth Advisors's PFE Position: Q4 2025 in Review

Long Run Wealth Advisors increased its Pfizer (PFE) stake by 1.1% in Q4 2025, buying an estimated $19.3K and bringing the position to 69,160 shares worth $1.72M. The position accounts for 0.32% of the portfolio, ranked #53.

Long Run Wealth Advisors first reported a position in PFE in Q4 2021 and has held it in 17 quarters since. The position peaked at $1.74M in Q3 2025. 2,905 funds tracked by Wall St. Rank hold PFE as of Q4 2025.

  • Long Run Wealth Advisors held 69,160 shares of Pfizer worth $1.72M as of Q4 2025.
  • Long Run Wealth Advisors bought 764 Pfizer shares in Q4 2025, an estimated $19.3K.
  • Pfizer made up 0.32% of Long Run Wealth Advisors's portfolio in Q4 2025, its #53 holding.
  • Long Run Wealth Advisors first reported a position in Pfizer in Q4 2021 and has held it in 17 quarters since.
  • Long Run Wealth Advisors's Pfizer position peaked at $1.74M in Q3 2025.
  • 2,905 funds tracked by Wall St. Rank held Pfizer as of Q4 2025.

Based on Long Run Wealth Advisors's 13F filing for Q4 2025, filed 2 Feb 2026.